AstraZeneca, Daiichi Sankyo seek US FDA’s accelerated approval for datopotamab deruxtecan to treat advanced EGFR-mutated NSCLC ...

Arch Biopartners doses first patient in Canada for phase II trial of LSALT peptide to treat cardiac surgery associated acute kidney injury: Toronto Wednesday, November 13, 2024, 1 ...

Boehringer Ingelheim and the Mary Tyler Moore Vision Initiative (MTM Vision) jointly announce the start of a long-term collaboration as Boehringer becomes the first pharmaceutical company to join the ...

Govt should roll out comprehensive National Cancer Care Policy with dedicated funding outlay: FICCI-EY Parthenon Report: Our ...

AstraZeneca to invest $3.5 billion in R&D and manufacturing in US: Cambridge, UK Wednesday, November 13, 2024, 09:00 Hrs [IST] AstraZeneca, a global, science-led biopharmaceutical ...

The All India Organization of Chemists and Druggists (AIOCD) has recently expressed concern over the partnership between Swiggy Instamart and PharmEasy for a rapid drug delivery model in the country.

The National Accreditation Board for Testing and Calibration Laboratories (NABL), under the Quality Council of India (QCI), has announced a collaborative effort with Man-Made Textile Research ...

An inter-ministerial committee formed by the Union health ministry has recommended amendments to the Food Safety and Standards Act, 2006 and regulations on nutraceuticals and health supplements, to ...

The Indian pharmaceutical industry is advocating for enhanced fire safety measures and improved insurance coverage for employees working in pharmaceutical facilities. Given the highly volatile and ...

The centrally sponsored scheme for strengthening of medical devices industry (SMDI), launched by the Central government last week, was widely welcomed by the medical devices industry in the country.

Oncoinvent announces positive interim results from phase 1/2a studies of Radspherin for treatment of peritoneal carcinomatosis: Oslo, Norway Tuesday, November 12, 2024, 18:00 Hrs ...

EnteroBiotix Limited, a clinical-stage biotechnology company focussed on developing best-in-class full-spectrum microbiome therapeutics, announced positive results from its phase 1b IMPuLCE study ...